Cureus

Resmetirom for Treating Fatty Liver Disease Linked to Metabolic Problems: Review of Current Evidence and Potential Benefits

Updated

Abstract

Resmetirom is a recently FDA-approved treatment for metabolic dysfunction-associated steatohepatitis (MASH).

  • Resmetirom is associated with the reduction of intra-hepatic lipids and improvement in liver tissue health.
  • Key outcomes show that resmetirom may lead to resolution of non-alcoholic steatohepatitis (NASH) and improvement in fibrosis in a significant percentage of patients.
  • Common gastrointestinal side effects are noted, but the drug maintains a favorable safety profile.
  • Ongoing phase 3 trials aim to provide essential information on the long-term efficacy and safety of resmetirom.

Simplified

Full Text

We can’t show the full text here under this license.

Funding

Competing interests

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free